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TACI (transmembrane activator and calcium modulator and cyclophilin ligand [CAML] interactor) is a
part of a novel network of ligands and receptors involved in B-cell survival and isotype switching. The TACI
protein mediates its effects through CAML, an endoplasmic reticulum (ER)-localized protein that controls
Ca2 efflux. The adenovirus E3-6.7K protein prevents inflammatory responses and also confers resistance from
a variety of apoptotic stimuli and maintains ER Ca2 homeostasis; however, the mechanism of action is
unknown. Here, we provide evidence that E3-6.7K shares sequence homology with TACI and inhibits apoptosis
and ER Ca2 efflux through an interaction with CAML, a Ca2-modulating protein. We demonstrate a direct
interaction between E3-6.7K and CAML and reveal that the two proteins colocalize in an ER-like compartment.
Furthermore, the interaction between the two proteins is localized to the N-terminal domain of CAML and to
a 22-amino-acid region near the C terminus of E3-6.7K termed the CAML-binding domain (CBD). Mutational
analysis of the CBD showed that an interaction with CAML is required for E3-6.7K to inhibit thapsigargin-
induced apoptosis and ER Ca2 efflux. E3-6.7K appears to be the first virologue of TACI to be identified. It
targets CAML in a novel immunosubversive mechanism to alter ER Ca2 homeostasis, which consequently
inhibits inflammation and protects infected cells from apoptosis.
TACI (transmembrane activator and calcium modulator and
cyclophilin ligand [CAML] interactor), a member of the tumor
necrosis factor (TNF) family, is a receptor involved in B-cell
survival and isotype switching pathways. The extracellular li-
gands of TACI are BAFF (B-cell activating factor belonging
to the TNF family) and APRIL (a proliferation-inducing
ligand) (62). Both proteins share the ability to bind to TACI
and BCMA (B-cell maturation antigen) (42, 49). In addition,
BAFF interacts specifically with a third receptor termed BAFF-R
(48). Although the role of APRIL is less defined, BAFF plays
a very important role in B-cell survival and isotype switching
(1, 7). In addition, BAFF has been implicated in the develop-
ment of autoimmune disorders. Overexpression of BAFF leads
to autoimmunity in mice (28, 33), and patients with systemic
lupus erythematosus have elevated levels of BAFF (64). While
BAFF-R and BCMA are required for B-cell survival, TACI
has been shown to be a negative regulator (45). Antibodies to
TACI lead to the activation of NF-AT, NF-B, and AP1. The
TACI protein mediates its effects through CAML (58), an
endoplasmic reticulum (ER)-localized protein that controls
Ca2 efflux (4).
Although it had been implicated in numerous Ca2 signal
transduction pathways, the exact function of CAML is un-
known. It was initially identified as an important mediator of
the Ca2 signal transduction pathway in T cells. Acting down-
stream of the T-cell receptor, CAML causes an influx of Ca2
leading to the activation of NF-AT (4). CAML has three pu-
tative transmembrane domains at the C terminus, the last two
of which are necessary and sufficient for mediating the deple-
tion of Ca2 stores (24). In addition, CAML has been impli-
cated in transducing the signal from angiotensin II to NF-AT
through an interaction with ATRAP (angiotensin II type I
receptor-associated protein) (20). CAML has also been re-
ported to interact with epidermal growth factor receptor
(EGFR) (55) and the protein tyrosine kinase p56Lck (54).
Adenovirus is an important etiological agent which causes
acute respiratory and gastrointestinal infections worldwide.
The virus often establishes a persistent infection with no out-
ward signs of disease (16). Lymphocytes have long been sug-
gested to harbor adenovirus in a latent form (56), with recent
evidence pointing towards human mucosal T cells (17). In
order to remain persistent, adenovirus must have mechanisms
to suppress the host antiviral response that would otherwise act
to eliminate the virus. The early transcription region (E3) of
species C adenoviruses consists of a cassette of genes involved
in the modulation of the host immune response. E3-19K down-
regulates major histocompatibility complex class I, while other
E3 proteins such as 6.7K, 14.7K, and the complex formed by
10.4K and 14.5K, also known as receptor internalization and
degradation (RID) protein  (RID) and RID, respectively,
inhibit death receptor-induced apoptosis (19, 34, 38, 50, 52).
The smallest of the E3 proteins, 6.7K is a 61-amino-acid
glycoprotein that exists in three diverse membrane topologies:
the type III orientation (N luminal/C cytoplasmic, termed
NtmE3-6.7K), the opposite type II orientation (C luminal/N
cytoplasmic, termed CtmE3-6.7K), and the fully translocated
form (N and C termini both luminal, termed NCE3-6.7K) (37).
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E3-6.7K appears to have two separate yet not necessarily ex-
clusive roles in inhibiting apoptosis. The first demonstrated
function for E3-6.7K was that in conjunction with the RID
complex, E3-6.7K is able to down-regulate the TNF-related
apoptosis-inducing ligand (TRAIL) receptors. Although local-
ized primarily in the ER (61), a small fraction of E3-6.7K
reaches the plasma membrane, where it can interact with
RID (2). E3-6.7K was shown to be required for RID-medi-
ated down-regulation of TRAIL-R2 (2, 32). With regard to
TRAIL-R1, the requirement for E3-6.7K is less clear. One
group showed that E3-6.7K is necessary for the optimal down-
regulation of TRAIL-R1 (2), whereas another group showed
that the down-regulation of the receptor is independent of
E3-6.7K (52). The RID complex also down-regulates Fas (50),
TNF-R1 (15), and EGFR (51); however, E3-6.7K was not
shown to be required for any of these effects.
The second role of E3-6.7K involves the inhibition of apop-
tosis independent of other virus proteins. It protects trans-
fected cells against death receptor-mediated apoptosis induced
through Fas, TNF receptor, or TRAIL receptors. Cells ex-
pressing E3-6.7K also had reduced levels of apoptosis after
treatment with thapsigargin (38), a compound that induces
apoptosis by mimicking a sustained Ca2 flux. An examination
of ER Ca2 flux showed that the presence of E3-6.7K resulted
in a reduction of thapsigargin-induced Ca2 release, thereby
suggesting a role in events that regulate Ca2 homeostasis.
The mechanism by which E3-6.7K regulates Ca2 homeosta-
sis remains to be elucidated. However, it joins a very small
family of other viral proteins that modulate cellular Ca2. In
fact, only two other viral proteins are known to inhibit apop-
tosis by altering cellular Ca2: the coxsackievirus 2B protein
and the Kaposi’s sarcoma-associated herpesvirus K7 protein.
The 2B protein is a small (97- to 99-amino-acid) transmem-
brane protein localized to the ER and Golgi membranes,
where it appears to form pores as homomultimers (57). These
pores reduce mobilizable Ca2 stores available to induce apop-
tosis (6). The K7 protein is a small (126-amino-acid) trans-
membrane protein localized to the mitochondria and to a
lesser extent to the ER (59). K7 alters the kinetics and ampli-
tude of cellular Ca2 fluxes and inhibits apoptosis induced by
thapsigargin through an interaction with CAML (14).
The small size of E3-6.7K and its lack of sequence homology
with 2B or other channel proteins suggest that it is unlikely to
form pores on its own. A more likely hypothesis is that E3-6.7K
interacts with a cellular protein involved in Ca2 homeostasis.
MATERIALS AND METHODS
Cell lines and culture conditions. The human T-cell leukemia line Jurkat,
clone E6-1, and the human cervical carcinoma cell line HeLa were obtained from
American Type Culture Collection (Manassas, VA). Jurkat cells were main-
tained in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 20 mM
HEPES. HeLa cells were maintained in Dulbecco’s modified Eagle medium
(Invitrogen) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1
mM sodium pyruvate, and 20 mM HEPES.
Plasmid constructs. Full-length E3-6.7K, truncations of E3-6.7K, and full-
length human TACI DNA were cloned into pGBKT7 (Clontech, Mountain
View, CA), and DNAs for full-length human CAML or the N-terminal region of
CAML (NT-CAML) were cloned into pGADT7 (Clontech) by PCR using for-
ward primers containing an NdeI site and reverse primers containing a BamHI
site. For E3-6.7K and its truncations, the template DNA consisted of the EcoRI
D fragment of the E3 region of adenovirus type 2 (Ad2) (a kind gift from
W. S. M. Wold); for TACI, the template DNA was IMAGE clone ID 5213128
(Incyte Genomics, Wilmington, DE), which contains full-length human TACI
cDNA; and for CAML and NT-CAML, the template DNA was IMAGE clone
ID 3884754 (Incyte Genomics), which contains the full-length human CAML
cDNA. E3-6.7K DNA was also cloned into the green fluorescent protein (GFP)
mammalian expression vector pIRES-hrGFP-1a (Stratagene) and in frame with
yellow fluorescent protein (YFP) at the 3 end in pEFYP-C1 (Clontech) to
generate piGFP/6.7K and pYFP-6.7K, respectively. The cysteine mutations of
E3-6.7K in pGBKT7 and pIRES-hrGFP-1a were introduced by PCR-based mu-
tagenesis (5). CAML and NT-CAML DNA were also cloned into pcDNA 3.1
(Invitrogen) in frame with an N-terminal hemagglutinin (HA) tag to produce
pcDNA-HA-CAML and pcDNA-HA-NT-CAML, respectively.
Yeast two-hybrid assay. The yeast two-hybrid assay was performed using the
Saccharomyces cerevisiae AH109 strain (Clontech), which contains the GAL4-
inducible reporter genes His and Ade2 (26). The cells were transformed with
appropriate pGBKT7 bait and pGADT7 prey constructs using the polyethylene
glycol/lithium acetate method (18) and grown on minimal synthetic dropout (SD)
medium in the absence of Leu and Thr (SD-LT). As the vectors pGBKT7 and
pGADT7 contain TRP1 and LEU2 genes, respectively, growth on SD-LT ensures
that both vectors are present. Interactions between bait and prey proteins were
tested by plating colonies on SD medium lacking Leu, Thr, Ade, and His (SD-
LTAH). Growth on SD-LTAH indicated an interaction between the two pro-
teins. Transformed yeast cells were grown for 72 h at 30°C on selective medium.
Quantification of yeast two-hybrid interactions was measured by yeast growth
curve analysis from growth in selective medium, as previously described (10).
Briefly, individual colonies were used to inoculate liquid SD-LT medium and
were shaken at 200 rpm at 30°C overnight. The overnight cultures were diluted
1,000-fold in SD-LTAH. Cells were also diluted in SD-LT to confirmed viability.
The SD-LTAH cultures were incubated at 30°C with continuous shaking at 200
rpm, and the optical density was measured at 595 nm in an Spectronic BioMate
3 spectrophotometer (Thermo Electron Corporation, Waltham, MA) every 24 h
for 4 days. Differential optical density values were calculated for each day, and
the highest value was divided by the day the measurement was taken to give a
growth rate for each culture.
In vitro transcription and translation. Radiolabeled E3-6.7K and CAML were
prepared using the TnT T7 quick coupled transcription/translation systems (Pro-
mega, Madison, WI) according to the manufacturer’s protocol by use of
pGBKT7-E3-6.7K and pGADT7-CAML, respectively, as templates. Each reac-
tion was carried out in the presence of 20 Ci of Redivue L-[35S]methionine
(Amersham Biosciences, Piscataway, NJ) and 0.6 l of canine pancreatic micro-
somal membranes (Promega) for every 40-l reaction mixture. The pGBKT7
and pGADT7 vectors contain a T7 RNA polymerase promoter and either a
c-Myc or an HA epitope tag, respectively. The tag is incorporated at the N
terminus of the protein.
Immunoprecipitation and SDS-PAGE analysis. The mixture from the in vitro
transcription/translation reaction was diluted in 10 volumes of TNE buffer (50
mM Tris [pH 7.5], 150 mM NaCl, and 10 mM EDTA) and centrifuged for 3 min
at 12,000  g. The microsomal pellet was washed once with TNE and then
solubilized in lysis buffer (50 mM Tris [pH 7.5], 300 mM NaCl, 0.5% Triton
X-100) supplemented with Complete Mini (Roche, Laval, QC), a protease in-
hibitor cocktail. Samples were precleared for 1 h with Protein A beads (Clon-
tech) and then immunoprecipitated from the supernatant with either a c-Myc
monoclonal antibody (mAb) or an HA polyclonal antibody (Clontech) for 1 h at
room temperature. The immune complexes were purified with Protein A beads
followed by five washes with TNE containing 1% Tween 20. Bead slurries were
boiled in sodium dodecyl sulfate (SDS) sample buffer and run on a 12% SDS-
polyacrylamide gel electrophoresis (PAGE) gel. After electrophoresis, the gel
was fixed and dried onto Whatman 3MM paper before being exposed to a
phosphorimaging screen and evaluated using a phosphorimager SI and Image-
Quant software (Amersham Biosciences).
Immunofluorescence staining. HeLa cells were transiently transfected with the
indicated plasmids by use of FuGENE 6 (Roche). Transfected cells were fixed
with 2% paraformaldehyde for 20 min and permeabilized with 0.1% saponin in
2% bovine serum albumin (BSA) in phosphate-buffered saline for 15 min. Cells
were then blocked with 2% BSA for 1 h and reacted with 500 ng/ml 3F10 rat
anti-HA high-affinity primary antibody (Roche) in 2% BSA for 30 min. After
incubation, the cells were washed five times with 2% BSA, incubated with 1:500
diluted Alexa Fluor 568 goat anti-rat secondary antibody (Molecular Probes,
Eugene, OR) in 2% BSA for 30 min at room temperature in the dark, and
washed five times with 2% BSA. Cells were treated with SlowFade antifade
(Molecular Probes) and analyzed by confocal microscopy using a Bio-Rad Ra-
diance 2000 on a Nikon Eclipse TE300 with MaiTia sapphire laser and using
Lasersharp software (Bio-Rad, Hercules, CA).
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Annexin V–Alexa-647 apoptosis assays. Jurkat cells (1  107) were transiently
transfected with 20 g of the appropriate plasmid by electroporation with a
Bio-Rad Gene Pulser Xcell at 250 V and 950 F. At 24 h after electroporation,
apoptosis was induced in 1.2  106 cells with 8 M thapsigargin (Sigma) for 24 h.
Apoptosis was assayed by measuring externalization of phosphatidylserine with
annexin V conjugated to Alexa Fluor 647 (Molecular Probes) according the
manufacturer’s protocol using propidium iodide (PI) as a dead-cell counterstain.
Fluorescence-activated cell sorting (FACS) was performed with a FACSCalibur
instrument (Becton Dickinson) and analyzed with FlowJo software (Tree Star,
Ashland, OR).
Ratiometric intracellular [Ca2] determination. Jurkat cells (1  107) were
transiently transfected with 20 g of the appropriate plasmid by electroporation
with a Bio-Rad Gene Pulser Xcell at 250 V and 950 F. Intracellular Ca2 levels
were measured using the ratiometric Ca2 indicator Indo-1 acetoxymethyl ester
dye (Molecular Probes) according to the manufacturer’s recommendations. In
brief, 24 h after electroporation, cells were washed once with Opti-MEM (In-
vitrogen) and then loaded at 1  107 cells/ml with 2 M Indo-1 for 1 h at 37°C
in Opti-MEM. Cells were then washed 2 times with Opti-MEM, resuspended at
1  107 cells/ml in Opti-MEM, and kept on ice until analyzed. For each analysis,
100 l of cell suspension (1  106 cells) was added to 1.9 ml of Opti-MEM
prewarmed to 37°C. Indo-1-loaded cells were then examined with a FACSVantage
SE flow cytometer (BD Bioscience) equipped with a UV laser and appropriate
filters for the 405- and 485-nm wavelengths. After the establishment of a stable
baseline for the first 2 min, the cells were simulated with 10 nM thapsigargin and
monitored for another 6 min. The change in intracellular Ca2 levels was de-
termined through the ratio of emission signals of Indo-1 at 405 nm and 485 nm,
representing the ratio of Ca2-bound to Ca2-free Indo-1, respectively. The
kinetic analysis was performed using FlowJo software.
Statistical analysis. Statistical significance for the quantitative yeast growth
curve analysis was determined by the analysis of variance test using GraphPad
Prism software (GraphPad Software, San Diego, CA). For all tests, P values of
0.01 were considered to indicate statistical significance. All error bars shown
represent standard deviation.
To compare FACS histograms for the analysis of apoptotic cell populations, a
probability binning algorithm was used (multisample comparison in FlowJo).
This algorithm determines the probability that two or more FACS data distri-
butions are different (43). When the probability binning metric, T(	), is 
4, the
populations differ by more than 4 standard deviations, giving the probability that
the two populations are different with a P value of 0.01 (99% confidence).
RESULTS
Determination of E3-6.7K as a viral homologue to TACI. We
have shown that E3-6.7K, in the absence of other viral pro-
teins, is able to protect transfected cells from death receptor-
induced apoptosis; however, the mechanism of action was un-
known. We hypothesized that E3-6.7K may be a viral
homologue of a human protein. A BLAST search of E3-6.7K
against the human nonredundant protein database revealed no
matches, so we expanded our search for distantly related pro-
teins by use of a pattern-hit-initiated BLAST search. Species B
adenoviruses encode a 16-kDa homologue of the E3-6.7K pro-
tein, termed E3-16K (21). A consensus was obtained from
aligning E3-6.7K from Ad2 and Ad5 with its homologue E3-
16K from Ad3 and Ad7. We performed a pattern-hit-initiated
BLAST search using Ad2 E3-6.7K as the query and the con-
sensus as the pattern against the human nonredundant protein
database and got one hit, which was for TACI. TACI, through
an interaction with CAML, controls ER Ca2 efflux and the
activation of NF-AT (58). E3-6.7K and TACI share sequence
similarity within the well-conserved carboxyl terminus of E3-
6.7K (Fig. 1).
The CAML-binding domain (CBD) of the 293-amino-acid
TACI has not been determined; however, von Bülow and
Bram (58) in their initial characterization of the protein
showed that residues 162 to 293 are able to bind to CAML.
Another group, while demonstrating a TRAF binding domain
(BD) for TACI, determined that residues 1 to 212 of TACI are
able to bind to CAML (63). Taken together, these findings
indicate that the CBD of TACI is localized between residues
162 and 212 (Fig. 1). Interestingly, this domain of TACI over-
laps with the region of TACI that shares sequence similarity
with E3-6.7K, suggesting that E3-6.7K may also bind to
CAML.
E3-6.7K binds to CAML. To investigate whether E3-6.7K
binds to CAML, we used a yeast two-hybrid approach. The
coding DNA for a bait protein was cloned in frame with the
GAL4 DNA-BD of pGBKT7, while the DNA for the prey
protein was cloned in frame with the GAL4 DNA activation
domain of pGADT7. The yeast strain AH109 was transformed
FIG. 1. Sequence comparison of E3-6.7K, E3-16K, and TACI. E3-6.7K from Ad2 and Ad5 (species C) and E3-16K from Ad3 and Ad7 (species
B) were aligned with human and mouse TACI by use of CLUSTAL_X (47) and formatted with GeneDoc. Shaded regions show sequence similarity.
The consensus sequence is below the alignment (key: 6  ILV, 4  KR, 1  ND). The boxed region indicates the CBD of human TACI. The dotted
boxed region indicates CT-E3-6.7K.
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with bait and prey plasmids, and positive interactions were
identified based on the activation of the ADE2 and HIS3 re-
porter genes as visualized by growth of the transformants on
SD-LTAH selection plates. TACI was originally discovered
from a yeast two-hybrid screen using CAML as bait (58). For
the current study, TACI was used as a positive control and
bound to CAML in our system (Fig. 2A). NT-CAML, consist-
ing of residues 1 to 201, is the TACI-interacting domain (58);
therefore, it may also bind to E3-6.7K. We show using the yeast
two-hybrid system that E3-6.7 K is able to bind to CAML and
NT-CAML (Fig. 2A). The alignment in Fig. 1 shows that the C
terminus of E3-6.7K (residues 35 to 61) contains the highest
sequence similarity to TACI. This region, termed CT-E3-6.7K,
did not interact with CAML or NT-CAML, indicating that
additional residues were required for an interaction with
CAML (Fig. 2A). BD alone showed no growth with CAML or
NT-CAML, and the activation domain alone showed no
growth with E3-6.7K, CT-E3-6.7K, or TACI (data not shown).
Unfortunately, no antibodies to E3-6.7K were available;
therefore, pull-down assays of E3-6.7K and CAML from virus-
infected cells were not possible. Instead, we tested the binding
of CAML to E3-6.7K in vitro by generating HA-tagged CAML
and c-Myc-tagged E3-6.7K individually or together by in vitro
transcription/translation in the presence of L-[35S]methionine
and microsomes. The translated products were immunopre-
cipitated with either anti-c-Myc or anti-HA antibodies. The
immune complexes were then purified with Protein A-Sepha-
rose, separated by SDS-PAGE, and examined following expo-
sure to a phosphorimager screen. When made individually,
c-Myc-E3-6.7K and HA-CAML are immunoprecipitated with
anti-Myc and anti-HA antibodies, respectively (Fig. 2B, lanes 1
and 2). When c-Myc-E3-6.7K and HA-CAML are made to-
gether, both proteins are immunoprecipitated independent of
the antibody used, indicating that they form a complex (Fig.
2B, lanes 3 and 4). Additional specificity controls were con-
ducted using c-Myc-tagged p53 and HA-tagged simian virus 40
large T antigen provided by the kit supplier. These controls
demonstrated that the in vitro system faithfully translated the
specific mRNAs and provided specificity controls to ensure
that the proteins cross-precipitated using HA-CAML and
c-Myc-E3-6.7K were specific and unique (data not shown).
This confirms the earlier yeast two-hybrid assay results, veri-
fying that the E3-6.7K and CAML proteins interact.
E3-6.7K colocalizes with CAML. Although a small subset of
E3-6.7K reaches the plasma membrane of cells and associates
with the adenovirus RID complex (2, 32), the majority is in-
tracellular and localized to the ER membrane (61). CAML is
not found on the cell surface but is also a resident of the ER
(4). To determine if CAML and E3-6.7K colocalize, HeLa cells
were transfected with pYFP or pYFP-6.7K, alone or in com-
bination with pcDNA/HA-CAML. After 72 h, the cells were
stained for HA-tagged CAML. First, it was demonstrated that
the anti-FLAG mAb did not nonspecifically stain HeLa cells
transfected with pYFP or pYFP-6.7K alone (Fig. 3A and B).
YFP alone was distributed diffusely throughout the cell (Fig.
3A and C), as has been demonstrated before for YFP in HeLa
cells (41). In comparison, YFP-tagged E3-6.7K had a punctate,
perinuclear distribution reminiscent of ER localization (Fig.
3B and D). As expected, cells transfected with pcDNA/HA-
CAML showed similar perinuclear ER staining with the anti-HA
mAb (Fig. 3C and D). In fact, when the fluorescent signals of
HA-CAML and YFP-6.7K were superimposed, a white image
was uniformly obtained (Fig. 3D). Superposition of the YFP
and HA-CAML fluorescent signals resulted in little or no
white (Fig. 3C). These results provide evidence that CAML
and E3-6.7K localize predominantly in the same subcellular
compartments.
To further confirm an interaction between E3-6.7K and
CAML, HeLa cells transfected with pYFP or pYFP-6.7K and
pcDNA/HA-NT-CAML were analyzed by confocal micros-
copy. NT-CAML is missing the transmembrane domains found
in the C terminus, so this domain is cytoplasmic (25). NT-
CAML does contain the TACI BD, and according to the yeast
two-hybrid results (Fig. 2A) it binds to E3-6.7K as well. Cells
transfected with pcDNA/HA-NT-CAML displayed cytoplas-
mic staining with the anti-HA mAb (Fig. 3E and F), and
although YFP was cytoplasmic as well, there was no white
when the images were overlaid (Fig. 3E). In contrast, super-
position of the YFP-6.7K and HA-NT-CAML fluorescent sig-
FIG. 2. E3-6.7K interacts with CAML. (A) Yeast two-hybrid assay.
AH109 cells were transformed with E3-6.7K, CT-E3-6.7K, or TACI
DNA in pGBKT7 and CAML or NT-CAML DNA in pGADT7 and
grown on SD-LT to select for the presence of plasmids. Yeast cells
were replated on SD-LTAH to select for protein interaction. Growth
on SD-LTAH indicates an interaction between the two proteins.
(B) Immunoprecipitation (IP) of E3-6.7K and CAML. The indicated
DNA was transcribed and translated in vitro in the presence of micro-
somes and L-[35S]methionine. The newly synthesized proteins were
immunoprecipitated with the indicated antibody followed by SDS-
PAGE and exposure to a phosphorimager screen. The positions of
protein molecular mass markers are shown on the left. OD595, optical
density at 595 nm; wt, wild type; , Ab.
910 GRANT ET AL. CLIN. VACCINE IMMUNOL.
 on M









nals resulted in bands of white where YFP-6.7K perinuclear
staining meets the cytoplasmic staining of HA-NT-CAML
(Fig. 3F). This suggests that an interaction between E3-6.7K
and NT-CAML is bringing cytoplasmic NT-CAML to the pe-
riphery of ER, which explains the colocalization of the two
proteins.
Defining the CBD. Although CT-E3-6.7K contains the re-
gion of sequence similarity to TACI, it does not interact with
CAML (Fig. 2A), suggesting that the CBD of E3-6.7K requires
additional N-terminal residues. To localize the CAML-binding
region of E3-6.7K, we generated truncations of E3-6.7K from
the C terminus in 5-amino-acid increments. In addition, to
determine the N-terminal boundary, we added amino acids in
5-amino-acid increments to CT-E3-6.7K. E3-6.7K truncations
were assayed for binding to CAML by use of the yeast two-
hybrid assay. From the C terminus, 15 residues were capable of
being removed and CAML binding still occurred, while 10
additional residues were required at the N terminus of CT-E3-
6.7K for an interaction with CAML (Fig. 4A). The resulting
domain boundaries suggest a 22-amino-acid region of E3-6.7K
FIG. 3. Colocalization of E3-6.7K with CAML or NT-CAML. (A-F) HeLa cells were transfected with the indicated DNA. Cells were costained
with 3F10 anti-HA rat mAb (-HA) and Alexa 568-conjugated anti-rat secondary antibody (magenta). Immunofluorescence was examined using
a Bio-Rad Radiance 2000 confocal microscope, and a representative optical section of each transfection is presented. YFP exhibits green
fluorescence. White indicates colocalization. The white scale bar is 10 m in length. Data were similar in three independent experiments.
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responsible for CAML binding. This CBD was generated and
found to be able to interact with CAML (Fig. 4A). Interest-
ingly, the CBD of E3-6.7K overlaps with the region of TACI
known to bind CAML (Fig. 4B).
Conserved cysteines are required for CAML binding. Amino
acid conservation between species is often a good indication of
the importance of particular residues in the function of a given
protein domain. An examination of the CBD reveals that 7 of
FIG. 4. CBD of E3-6.7K. (A) Determining the CBD. Two sets of E3-6.7K truncations were made: minus () truncations removed amino acids
in 5-amino-acid increments from the C terminus of the protein, and plus () truncations added amino acids in 5-amino-acid increments to the N
terminus of CT-E3-6.7K. DNA encoding the truncations was cloned into pGBKT7 and transformed along with pGADT7-CAML into AH109 cells
followed by selection for plasmids on SD-LT. An interaction with CAML was selected for by growing the yeast on SD-LTAH. , growth on
SD-LTAH, indicating an interaction with CAML; , no growth on SD-LTAH, suggesting no interaction with CAML. (B) Comparison of the CBDs
of E3-6.7K and TACI. A consensus sequence is below the alignment (key: 6  ILV, 4  KR).
FIG. 5. Cysteine mutational analysis of CBD. (A) Sequence of the wild-type (wt) E3-6.7K and cysteine mutants. The dotted box indicates the
CBD. (B) Quantitative growth rate analysis of yeast transformed with the indicated pGBKT7-6.7K mutant or the pGBKT7 vector alone (VA) and
pGADT7-CAML grown in liquid SD-LTAH. *, P  0.01 compared to the wild type. Data represent an average of triplicate measurements, and
error bars indicate standard deviation. OD595, optical density at 595 nm.
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the 22 residues are conserved in E3-6.7K, E3-16K, and TACI
(Fig. 4B). Four of the conserved amino acids are aliphatic and
therefore very nonreactive and abundant, so attention was
turned to the three conserved cysteines. Besides being found in
disulfide bonds, cysteines are common in protein active and
binding sites. In addition, cysteines are uncommon in proteins,
with only tryptophan being more rarely found (3). Therefore,
the presence of conserved cysteines in the CBD indicates that
they may be important in CAML binding and thus may also
affect the functions of E3-6.7K, such as its ability to inhibit
apoptosis. To test this, three different mutants of E3-6.7K were
generated using site-directed mutagenesis on the pGBKT7-
6.7K plasmid, altering the cysteine codon TGC to the alanine
codon GCC. Alanine was chosen since it is a neutral substitu-
tion (22). E3-6.7K (A.CC) has the Cys36Ala mutation, E3-
6.7K (C.AA) has both the Cys42Ala and Cys43Ala mutations,
and E3-6.7K (A.AA) has all three cysteines mutated to alanine
(Fig. 5A). The yeast strain AH109 was transformed with
pGADT7-CAML and either pGBKT7-6.7K or with one of the
newly constructed plasmids encoding an E3-6.7K mutant. An
interaction between the E3-6.7K mutants and CAML was
quantified with a yeast growth curve analysis (Fig. 5B). All the
E3-6.7K mutants had significantly reduced growth rates com-
pared to that of wild-type E3-6.7K, indicating a reduced ability
to interact with CAML. The cysteines may be involved directly
in binding or may alter the structure or topology of E3-6.7K,
thus interfering with CAML binding.
E3-6.7K interaction with CAML is necessary for inhibiting
apoptosis. The next step was to show that an interaction with
CAML is required for E3-6.7K to inhibit apoptosis. In addition
to death receptor-induced apoptosis, E3-6.7K confers a similar
degree of protection against thapsigargin, a mediator of apop-
tosis that acts intracellularly by mimicking a sustained Ca2
flux (27). Thapsigargin, a sesquiterpene lactone that selectively
inhibits the ER Ca2-ATPase that directs Ca2 uptake into
the ER, has been shown to induce apoptosis in Jurkat cells at
high doses (46). The mammalian expression plasmid piGFP/
6.7K was mutated by site-directed mutagenesis to produce the
three same mutants generated for the binding studies: piGFP/
6.7K (A.CC), piGFP/6.7K (C.AA), and piGFP/6.7K (A.AA).
Jurkat cells were transiently transfected with the vector piGFP
alone, with piGFP/6.7K, or with one of the piGFP/6.7K mu-
tants. After 24 h, the cells were stimulated with 8 M thapsi-
gargin for a further 24 h before apoptosis was measured with
annexin V. One of the signs of apoptosis is a loss of phospho-
lipid asymmetry, leading to the exposure of phosphatidylserine
on the outer leaflet of the plasma membrane (13). Annexin V
preferentially binds to phosphatidylserine, allowing for a sim-
ple assay of apoptosis on a per-cell basis by flow cytometry
(29). In addition, annexin V methods have been shown to be as
sensitive and specific as terminal deoxynucleotidyltransferase-
mediated dUTP-biotin nick end labeling apoptotic assays (31).
Cells with piGFP alone were 78% apoptotic, while cells con-
taining E3-6.7K were only 52% apoptotic, consistent with ear-
lier findings (Fig. 6) (38). However, in the presence of any of
the E3-6.7K mutants, there was no significant reduction in
apoptotic cells, implying that an interaction with CAML is
necessary for E3-6.7K to inhibit apoptosis.
E3-6.7K interaction with CAML is necessary for inhibiting
ER Ca2 flux. E3-6.7K was shown previously to reduce the
efflux of Ca2 from the ER in the response to thapsigargin
(38). Therefore, it was imperative to test whether non-CAML-
binding mutants of E3-6.7K altered intracellular Ca2 kinetics.
Jurkat cells were transiently transfected either with the vector
piGFP alone, with piGFP/6.7K, or with one of the piGFP/6.7K
mutants. After 24 h, the cells were loaded with the Ca2-
sensitive fluorophore Indo-1. Intracellular Ca2 was assayed
by FACS and represented using a ratiometric value of the
amount of Ca2-bound Indo-1 to the amount of Ca2-free
Indo-1 per cell. The GFP-positive population was gated, and
baseline Ca2 measurements were taken for 2 min, at which
time cells were treated with 10 nM thapsigargin. Jurkat cells
expressing E3-6.7K had slower kinetics in the elevation of
FIG. 6. E3-6.7K cysteine mutants unable to inhibit apoptosis. At
24 h after electroporation with the indicated E3-6.7K construct or with
the piGFP vector alone (VA), Jurkat cells were treated with 8 M
thapsigargin for 24 h. Following treatment, cells were stained with
annexin V–Alexa-648, indicating the externalization of phosphatidyl-
serine, and with PI as a dead-cell counterstain. Cells were analyzed for
annexin V staining by gating on GFP-positive and PI-negative cells.
The m1 gate indicates the apoptotic cell population and is shown as the
percentage of GFP-positive PI-negative cells. The asterisk indicates
that apoptotic population was significantly reduced compared to what
was seen for VA (P  0.01). Data were similar in three independent
experiments. wt, wild type.
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cytosolic Ca2 concentration than did cells expressing GFP
alone (Fig. 7). In contrast, the expression of any of the E3-6.7K
mutants resulted in cytosolic Ca2 kinetics identical to that
seen for GFP expression alone. Thus, these results demon-
strate that unlike wild-type E3-6.7K, mutants of E3-6.7K that
do not interact with CAML have no effect on the kinetics of
intracellular Ca2 concentration in response to apoptotic
stimuli.
DISCUSSION
It was demonstrated that the adenovirus protein E3-6.7K
has sequence similarity to the cellular protein TACI and that
E3-6.7K interacts directly with CAML, an important mediator
of Ca2 homeostasis to inhibit apoptosis. The E3-6.7K protein
was observed to bind to NT-CAML, the same domain shown to
interact with TACI. In fact, all known CAML-binding proteins
have been demonstrated to interact with NT-CAML. NT-
CAML is completely cytoplasmic and is believed to be a reg-
ulatory domain. Recently we have shown E3-6.7K to exist in
three diverse membrane topologies (Fig. 8) (37). Depending
on the topology of E3-6.7K, the CBD can be located either in
the cytosol or in the lumen of the ER. E3-6.7K interacts with
NT-CAML, indicating that the interaction occurs in the cy-
tosol. Consequently, the likely binding partner of CAML is
NtmE3-6.7K, as it is the only form to display the CBD in the
cytosol (Fig. 8) (36).
The CBD of E3-6.7K was defined to be a 22-amino-acid
domain necessary for binding to CAML. Interestingly, this
domain overlaps significantly with the CAML-binding region
of TACI (Fig. 4B). This suggests that there may be a common
domain employed by proteins that bind to CAML; however, a
thorough examination of all other proteins known to interact
with CAML revealed that none of them contain a similar
motif. EGFR and p56Lck have been shown to interact with
CAML through their tyrosine kinase domains (54, 55). CAML
does not appear to bind indiscriminately to kinases, as no
interaction was found with either of two other kinases, p59Fyn
and ZAP-70 (54). Clearly CAML is able to bind to numerous
proteins through multiple BDs, implying the importance of this
ubiquitously expressed protein. While not required for cellular
viability, CAML is required for early embryonic development
(55).
FIG. 7. E3-6.7K mutants do not inhibit thapsigargin-induced Ca2 flux. Jurkat cells were transfected with either the piGFP vector alone (VA),
piGFP/6.7K (wt), or one of the piGFP vectors encoding E3-6.7K mutants. After 24 h, the cells were loaded with Indo-1 in the presence of
extracellular Ca2. The GFP-positive population was gated and baseline Ca2 measurements were taken for 2 min, at which point thapsigargin
(TG) was added to a final concentration of 10 nM, and then the analysis was immediately resumed. Data were similar in three independent
experiments.
FIG. 8. Schematic of CAML and the different E3-6.7K topologies. The three topologies of E3-6.7K are shown, with the N and C termini labeled
as N and C, respectively. The dark gray region on E3-6.7K is the CBD and consists of residues 25 to 46. The N-terminal 201 residues of CAML,
labeled NT-CAML, are completely cytoplasmic and contain the E3-6.7K BD.
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The role of CAML in intracellular Ca2 regulation and
apoptosis is unresolved. CAML may modulate ER Ca2 by
forming Ca2 channels, or it may act directly or indirectly on
either preexisting Ca2 release channels or sarcoplasmic/ER
Ca2-ATPase (SERCA) pumps. By comparison, all these
Ca2-modulating mechanisms have been proposed for mem-
bers of the Bcl-2 family. Bcl-XL, a Bcl-2 homolog, is very
similar in structure to some pore-forming bacterial toxins (39).
Both Bcl-2 and Bcl-XL are able to form ion channels in syn-
thetic lipid membranes (35, 44), although neither has been
shown to conduct Ca2. As CAML has no apparent sequence
homology to known Ca2 channels (24), pore formation seems
unlikely although not entirely impossible. Recently, much at-
tention has focused on interactions of the Bcl-2-related pro-
teins with Ca2 release channels and pumps. Inositol 1,4,5-
trisphosphate receptors (IP3Rs) are the principal channel for
mobilizing Ca2 stores from the ER in almost all cell types.
Bcl-2 and Bcl-XL are both able to interact directly with IP3Rs
(8, 60). The IP3R–Bcl-2 interaction was increased in the ab-
sence of Bax and Bak (40), while tBid and Bax were able to
block the interaction between Bcl-XL and IP3R (60). The ratio
of pro- to antiapoptotic family members may be able to control
ER Ca2 levels through an IP3R-mediated Ca
2 leak. CAML
is unlikely to have a direct effect on IP3Rs, as it does not
comigrate with these Ca2 release channels in sucrose gradient
membrane fractionation (25). CAML does, however, comi-
grate with SERCA. Furthermore, immunofluorescence stain-
ing indicates that CAML and SERCA colocalize (25). Bcl-2
has been shown to interact with SERCA, as demonstrated by
coimmunoprecipitation (30). The addition of a truncated form
of Bcl-2 to sarcoplasmic reticulum vesicles resulted in the de-
stabilization of SERCA and a reduction in its Ca2-ATPase
activity (11). Dremina et al. (11) have suggested that Bcl-2 may
inhibit a fraction of the Ca2 pumps sufficient to decrease ER
Ca2 stores to levels below the threshold necessary to induce
proapoptotic Ca2 levels in mitochondria. The E3-6.7K–
CAML interaction may alter ER Ca2 stores through a similar
mechanism. In the end, a CAML–E3-6.7K interaction would
achieve the same goal of reducing Ca2 release from the ER
whether it inhibited the efflux of Ca2 from the ER or dimin-
ished the ER Ca2 stores through a Ca2 leak by inhibiting ER
Ca2 uptake. The second scenario seems more likely, as cells
overexpressing CAML result in a modest depletion of intra-
cellular Ca2 stores and a reduction in the amplitude of Ca2
waves in response to the agonist ATP (53). CAML may have a
natural function in apoptosis that viral proteins may be exploit-
ing, or perhaps CAML normally has no role in apoptosis but its
ability to affect Ca2 is subverted by the virus to inhibit cell
death. Interestingly, overexpression of CAML in a human B-
cell line has been shown to reduce apoptosis in response to
thapsigargin (14).
From the available data, a potential model starts to take
shape (Fig. 9). Early in the adenovirus infection, the E3-6.7K
protein is expressed and localizes primarily to the ER, where it
colocalizes with CAML. Through the CBD, E3-6.7K binds to
the N-terminal regulatory domain (residues 1 to 201) of
CAML, the same region that interacts with TACI. This inter-
action results in a depletion of intracellular Ca2 stores, pos-
sibly by inhibiting a fraction of SERCA Ca2 pumps. The
proapoptotic ER-to-mitochondrion Ca2 waves that result in
most apoptotic pathways are inhibited as a result of the re-
duced ER Ca2 steady-state levels. This general inhibition of
programmed cell death provides the virus with time to com-
plete viral replication and eventually assist in the maintenance
of a persistent infection.
In order to establish a persistent infection, viruses must
inhibit host defense mechanisms including apoptosis, interfer-
ons, NK cells, and cytotoxic T cells (23). The importance of
counteracting the host immune response is underscored by the
fact that almost one-third of the adenovirus genome is devoted
to the process. Proteins encoded by the E1, E3, and E4 genes,
the late protein L4-100K, and virus-associated RNAs all have
immune modulating properties. The combination of the anti-
apoptotic effect of E3-6.7K and the immune modulating abil-
FIG. 9. Proposed model of the E3-6.7K–CAML interaction preventing apoptosis. Ca2-ATPase pumps such as SERCA are responsible for
maintaining high luminal Ca2 concentration in the ER. High steady-state levels of ER Ca2 are required to release proapoptotic Ca2 waves that
occur in response to most apoptotic stimuli. In the presence of E3-6.7K, an interaction between E3-6.7K and CAML may result in lower
steady-state levels of ER Ca2 by inhibiting a fraction of SERCA Ca2 pumps. The lower ER Ca2 levels would not be high enough to release
proapoptotic Ca2 waves, thereby precluding cell death.
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ities of other adenovirus proteins likely contributes to the abil-
ity to establish persistence.
The E3-6.7K and K7 proteins are the first two members of a
novel class of viral antiapoptotic proteins that target CAML to
affect cellular Ca2 signaling. Although their targets and ulti-
mate goals are the same, their localizations and modes of
action are different. E3-6.7K is localized primarily to the ER,
while K7 is typically present at mitochondria. Even though
CAML is predominantly ER bound, this does not appear to be
a limitation for K7, as the ER and mitochondria are often in
close proximity (9). A major difference between K7 and E3-
6.7K is the opposite effects they have on thapsigargin-induced
Ca2 release. E3-6.7K reduces the efflux of Ca2, while K7
expression results in a slight increase in Ca2 release (14).
Although sustained high intracellular Ca2 levels contribute to
apoptosis, early up-regulation of cytoplasmic Ca2 levels may
protect cells against apoptosis (12).
Only three viral proteins are known to inhibit apoptosis by
altering cellular Ca2, and two of these interact with CAML.
The study of CAML and the E3-6.7K protein that targets it will
ultimately lead to a better understanding of the role of TACI,
immune evasion mechanisms, and viral persistence and also
provide a novel means to investigate cellular apoptotic path-
ways.
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